Literature DB >> 7029119

Acute hypercalcemic hypertension in man: role of hemodynamics, catecholamines, and renin.

C Marone, C Beretta-Piccoli, P Weidmann.   

Abstract

The effect of acute hypercalcemia on blood pressure, blood volume, hemodynamic parameters, plasma norepinephrine, epinephrine, dopamine, renin, and aldosterone concentrations was investigated. After 1 hour of equilibration, 10 patients received an infusion of calcium gluconate in 5% dextrose (calcium 15 mg/kg of body wt in 3 hours). The calcium infusion increased the mean serum calcium from 8.7 to 13.0 mg/dl, the systolic blood pressure from 144 +/- 10 to 184 +/- (SEM) 12 mm Hg (P less than 0.001), the diastolic pressure from 78 +/- 4 to 93 +/- 5 mm Hg (P less than 0.01). The plasma volume was decreased by 9% (P less than 0.001), whereas the hematocrit was increased (P less than 0.05). Heart rate and cardiac output remained unchanged. Total peripheral resistance was increased from 1643 +/- 223 to 2256 +/- 387 dyne.sec/cm5 (P less than 0.05). The plasma epinephrine concentration rose from 4.5 +/- 0.7 to 6.9 +/- 1.2 ng/dl (P less than 0.01). The plasma norepinephrine concentration was unchanged after 2 hours and increased only slightly after 3 hours of calcium infusion. Plasma renin, aldosterone, and dopamine concentrations were not significantly changed. These findings demonstrate that acute hypercalcemic hypertension is mediated by an increase in peripheral vascular resistance. Hypercalcemic hypertension may be induced by a direct effect of calcium on blood vessels; calcium-mediated increase in adrenal epinephrine release may play a mild contributory role, and plasma volume contraction, an inhibitory role.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7029119     DOI: 10.1038/ki.1981.109

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  The renin-angiotensin-aldosterone system and calcium-regulatory hormones.

Authors:  A Vaidya; J M Brown; J S Williams
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

2.  Modulation of platelet Ca2+ homeostasis by hypertensive plasma factor(s) derived from patients with early-stage renal disease.

Authors:  H Schiffl
Journal:  Klin Wochenschr       Date:  1991-12-11

3.  Platelet cytosolic free calcium concentration in hypertension associated with early stage kidney disease.

Authors:  H Schiffl
Journal:  Klin Wochenschr       Date:  1989-07-03

4.  Another family with acute vitamin D intoxication: another cause of familial hypercalcaemia.

Authors:  R B Thomson; J K Johnson
Journal:  Postgrad Med J       Date:  1986-11       Impact factor: 2.401

5.  The effect of graded calcium infusions on rhythmic blood pressure oscillations in normal man.

Authors:  M Munakata; Y Imai; K Mizunashi; J Hashimoto; H Sekino; Y Furukawa; K Abe
Journal:  Clin Auton Res       Date:  1995-02       Impact factor: 4.435

6.  Calcium modulation of the renin-aldosterone axis.

Authors:  L Porter; P R Conlin; J Scott; E M Brown; G El-Hajj Fuleihan
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

7.  Evidence that prostacyclin modulates the vascular actions of calcium in man.

Authors:  J L Nadler; M McKay; V Campese; J Vrbanac; R Horton
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

8.  Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure.

Authors:  J A Rodríguez-Portales; C Fardella
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

9.  Hypertension Secondary to PHPT: Cause or Coincidence?

Authors:  Helmut Schiffl; Susanne M Lang
Journal:  Int J Endocrinol       Date:  2011-03-07       Impact factor: 3.257

10.  The effects of low calcium dialysate on arterial compliance and vasoactive substances in patients with hemodialysis.

Authors:  Soo-Jeong Yoo; Dong-Jin Oh; Suk-Hee Yu
Journal:  Korean J Intern Med       Date:  2004-03       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.